United States

Back to map

Showing 251-260 of 325 grants

Title Institution Researcher Program Duration Total Award Amount
Type 1 Diabetes Consortium – Core and Prevention Workstream Critical Path Institute (C-Path) Sarah David Cures 01-July-2022 to 30-June-2025 $800.270,00
Towards FDA approval of Autonomous AI for diabetic retinopathy screening in youth Johns Hopkins University Risa Wolf Improving Lives 01-January-2023 to 31-December-2025 $637.547,20
Evaluating the Initial Efficacy, Acceptability, and Feasibility of BFST-DT, an Intervention for Improving Transition Readiness for Adolescents and Emerging Adults with Type 1 Diabetes Ann & Robert H. Lurie Children’s Hospital of Chicago Jaclyn Papadakis Improving Lives 01-May-2023 to 30-April-2027 $396.471,68
Addressing and mitigating sources of variability for the controlled and automated manufacturing of stem cell-derived beta (SC-beta) cells from pluripotent stem cells (PSCs) Advanced Regenerative Manufacturing Institute (ARMI) Thomas Bollenbach Cures 01-January-2023 to 31-December-2026 $1.241.255,20
Antigenic Targets of CD4 T cells across the stages of type 1 diabetes Regents of the University of Colorado Maki Nakayama Cures 01-August-2022 to 31-July-2026 $750.000,00
Mapping islet-reactive T cell responses by islet cell co-culture Trustees of the University of Pennsylvania Michael Betts Cures 01-July-2022 to 30-June-2025 $825.000,00
Expanding Technology Success into Novel Populations: Safety and Feasibility Testing of a Fully Closed Loop System in Adolescents and Young Adults with High Baseline HbA1c Values Regents of the University of Colorado Gregory Forlenza Improving Lives 01-November-2022 to 30-June-2025 $999.996,26
Localized immune modulation to enable long-term beta cell survival William Marsh Rice University Omid Veiseh Cures 01-September-2022 to 31-January-2026 $600.000,00
A Phase 2 Study Evaluating Short-Term Efficacy of Tonabersat (Xiflam) for Diabetic Macular Edema Jaeb Center for Health Research Adam Glassman Improving Lives 01-September-2022 to 01-January-2026 $273.424,00
Real time monitoring of a cell therapy product to assess and modify transplant health post-engraftment in patients with type 1 diabetes Minutia Katy Digovich Cures 01-November-2022 to 30-November-2025 $1.198.600,00